Advertisement

FGFR1 expression defines clinically distinct subtypes in pancreatic cancer

  • Farhan Haq
  • You-Na Sung
  • Inkeun Park
  • Mahmood Akhtar Kayani
  • Faizah Yousuf
  • Seung-Mo Hong
  • Sung-Min Ahn
Open Access
Research
Part of the following topical collections:
  1. Clinical translation

Abstract

Background

The clinical significance of fibroblast growth factor receptor 1 (FGFR1) protein expression in pancreatic cancer is largely unknown. In this study, we aimed investigate the clinical significance of FGFR1 expression in pancreatic cancer.

Methods

First, we investigated the relationship between FGFR pathway gene expression and clinicopathological data in three pancreatic cancer cohorts containing 313 cases. Subsequently, to confirm the findings from the discovery cohorts, we performed immunohistochemistry (IHC) of FGFR1 protein in a validation cohort of 205 pancreatic cancer cases.

Results

In discovery cohort 1, FGFR1 and Klotho beta (KLB) overexpression was associated with low tumor stage (P < 0.05), low tumor grade (P < 0.05), and better overall survival. Multivariate analysis predicted FGFR1 (P < 0.05) as a prognostic factor for better overall survival. In discovery cohorts 2 and 3, only FGFR1 overexpression was associated with better overall survival (P < 0.05). In the validation cohort, there were 15.7% and 61% strong and weak/moderate FGFR1-positive cases, respectively. FGFR1-positive cases showed better overall survival than FGFR1-negative cases (P < 0.05). Furthermore, multivariate analysis revealed FGFR1 positivity as an independent prognostic factor for better overall survival in pancreatic cancer patients (hazard ratio 0.677, 95% confidence interval 0.471–0.972, P = 0.035).

Conclusions

FGFR1 expression, as estimated by IHC, may be used to define clinically distinct subtypes in pancreatic cancer. Moreover, FGFR1-based subclassification of pancreatic cancer may lead to new therapeutic approaches for the FGFR1-positive subtype.

Keywords

FGFR1 Classification Prognosis Pancreatic cancer Anti-FGFR1 therapy 

Background

The fibroblast growth factor receptor (FGFR) pathway is one of the major carcinogenic pathways in cancer [1, 2, 3, 4, 5]. Genetic deregulation of fibroblast growth factors and their receptors plays an important role in the initiation and progression of different types of cancer [6, 7, 8, 9]. Helsten and colleagues [10] reported that the FGFR pathway is the third most frequently altered pathway in cancer, after the p53 and KRAS pathways. Accordingly, cancer drugs targeting the FGFR pathway have been tested in multiple cancers [1, 11]. Currently, phase I and phase II clinical trials of dovitinib, lucitanib, ponatinib, nintedanib, and pazopanib are underway in different solid tumors to block FGFR pathway activation [12, 13, 14, 15, 16].

In pancreatic cancer, aberrations in the FGFR pathway, particularly FGFR1 overexpression, have been reported. According to The Cancer Genome Atlas (TCGA) study on pancreatic cancer [17], FGFR1 is upregulated in approximately 5% of pancreatic cancers. Lehnen and colleagues [18] reported that FGFR1 was expressed in 4% (5/125) of pancreatic cancer cases, and FGFR1 amplification was observed in 2.6% (4/155). In contrast, Kornmann and colleagues [19] reported that 57% (4/7) of pancreatic cancer cases showed immunoreactivity for the IIIc splice variant of FGFR1 (FGFR1 IIIc). Nevertheless, the clinical significance of FGFR1 protein expression in pancreatic cancer is still largely unknown.

In this study, we aimed to investigate the clinical significance of FGFR1 overexpression in pancreatic cancer. First, we investigated the clinical significance of FGFR pathway genes using the gene expression and clinicopathological data from three pancreatic cancer cohorts containing 313 cases. Then, to confirm the findings from the discovery cohorts, we performed immunohistochemistry (IHC) targeting FGFR1 protein in a validation cohort of 205 pancreatic cancer cases.

Methodology

Data collection and screening

The overall study design is described in Additional file 1: Figure S1. Five FGFR pathway genes that are frequently dysregulated in multiple cancers, namely FGFR1, FGFR4, KLB (an FGFR co-receptor), FGF19 (the FGFR4 ligand), and FGF21 (the FGFR1 ligand), were selected for the analysis. Data from discovery cohort 1, consisting of 65 pancreatic cancer patients, were downloaded from the Gene Expression Omnibus database (Accession # GSE62452). Clinical features of discovery cohort 1, including stage, grade, and overall survival information, can be found in Additional file 1: Table S1. LogR expression values of data from the discovery cohort were generated from the Affymetrix Human Gene 1.0 ST array. In discovery cohort 1, the expression status of FGF19 (probe ID: 7950023), FGF21 (probe ID: 8030105), FGFR1 (probe ID: 8150318), FGFR4 (probe ID: 8110265), and KLB (probe ID: 8094679) were screened for the analysis. In discovery cohort 2, LogR expression values were generated using the RSTA Custom Affymetrix 2.0 array (Additional file 1: Figure S1). The expression status of FGF19 (probe ID: merck-NM_005117_at), FGF21 (probe ID: merck-NM_019113_at), FGFR1 (probe IDs: merck-NM_000604_at, merck-NM_023110_a_at, and merck2-NM_001174063.1), FGFR4 (probe ID: merck-NM_002011_at), and KLB (probe IDs: merck-BC033021_at and merck-NM_175737_a_at) was analyzed. In discovery cohort 3, RNA-seq data of 179 pancreatic cancers were analyzed (Additional file 1: Figure S1). The expression of FGF19, FGF21, FGFR1, FGFR4, and KLB was estimated using RNA-seq data with a z-score > 2.0. All detailed information from the pancreatic cancer dataset is available in the public cBioPortal database (Pancreatic Adenocarcinoma, TCGA, provisional).

Statistical analysis

The associations of FGF19, FGF21, FGFR1, FGFR4, and KLB expression with clinical features, including stage, grade, and survival, were calculated using χ2 and Fisher exact tests for the three discovery cohorts. Survival analysis was performed using Kaplan–Meier curves with log-rank (Mantel–Cox) P values. Cox proportional hazard regression and univariate and multivariable analyses were used to evaluate the association between gene expression and survival. Since the sample sizes of the discovery cohorts were small, the multivariable Cox regression model may have led to the overfitting of the data. Therefore, each gene was analyzed separately in combination with the clinical features in multivariable analysis. The hazard ratio (HR) and 95% confidence interval (CI) were also calculated for each factor. P values were two-sided, and P < 0.05 was considered to be statistically significant. All statistical analyses were performed with SPSS 21.0 software (IBM, Armonk, NY, USA).

Validation in 205 patients using IHC

Immunohistochemical labeling was performed in a validation cohort of 205 pancreatic cancer patients at the immunohistochemical laboratory of the Department of Pathology, Asan Medical Center. In brief, 4-μm-thick sections were deparaffinized with xylenes and hydrated in an ethanol series. Endogenous peroxidase activity was blocked by incubation in 3% H2O2 for 10 min, and then heat-induced antigen retrieval was performed. Primary antibodies were used with a Benchmark autostainer (Ventana Medical Systems, Tucson, AZ, USA) in accordance with the manufacturer’s protocol. Sections were incubated at room temperature for 32 min in primary antibody for FGFR1 (rabbit polyclonal, 1:100; Abnova, Taipei, Taiwan). The sections were then labeled with an automated immunostaining system and processed with an iView DAB detection kit (Benchmark XT, Ventana Medical Systems). Immunostained sections were lightly counterstained with hematoxylin, dehydrated in ethanol, and cleared in xylenes. Immunoreactivity was interpreted by light microscopic examination and independently evaluated by two pathologists, coauthors of this study (Y.N.S. and S.M.H.), who were blind to the clinicopathologic information. Cases were categorized as positive, weak positive and negative.

Results

Expression analysis of FGFR genes in discovery cohort 1

The logR expression values of five FGFR-related genes were dichotomized according to their median expressions (Additional file 1: Figure S2). FGFR1 had the highest expression, with a median enrichment of 5.922, whereas FGF21 had the lowest expression, with a median enrichment of 2.884. The expression level of FGFR4 was significantly correlated with those of FGF19 (Pearson Correlation = 0.30, P = 0.014), KLB (Pearson Correlation = 0.41, P = 0.001), and FGFR1 (Pearson Correlation = 0.29, P = 0.02). Notably, a strong correlation was observed between FGFR1 and KLB expression (Pearson’s correlation = 0.60, P < 0.001). FGF21 expression was not correlated with that of any of the other four genes.

Association between FGFR genes and clinical features in discovery cohort 1

According to Fisher’s exact test results, overexpression of FGFR4 (P < 0.001) and KLB (P = 0.005) were significantly associated with a low tumor grade. Overexpression of FGFR1 was significantly associated with both low tumor grade (P = 0.023) and low tumor stage (P = 0.023). FGF19 and FGF21 overexpression did not show any association with clinical features.

Next, the association between FGF19, FGF21, FGFR1, FGFR4, and KLB overexpression and the overall survival of pancreatic cancer patients was evaluated. According to univariate analysis, FGFR1 overexpression (HR 0.475, 95% CI 0.277–0.817, P = 0.007) and KLB overexpression (HR 0.536, 95% CI 0.318–0.903, P = 0.019) were significantly associated with better overall survival. In addition, FGFR4 overexpression showed a trend toward better overall survival, but it did not reach statistical significance (HR 0.610, 95% CI 0.370–1.008, P = 0.054) (Table 1). Kaplan–Meier curves also showed a clear separation between patients with high and low expression of FGFR1 (Fig. 1a), KLB (Fig. 1b), and FGFR4 (Fig. 1c). Furthermore, multivariable analysis was performed along with the prognostic factors (tumor stage and tumor grade) associated with pancreatic cancer. FGFR1 expression was the only prognostic factor for better overall survival (HR = 0.524, 95% CI 0.281–0.977, P = 0.042) (Table 2).
Table 1

Univariate analysis of FGFR-related genes for overall survival in cohort 1

Gene name

Hazard ratio (95% CI)

P value

FGFR1

0.475 (0.277–0.817)

0.007

FGFR4

0.610 (0.370–1.008)

0.054

FGF19

1.029 (0.630–1.682)

0.908

FGF21

0.853 (0.515–1.413)

0.537

KLB

0.536 (0.318–0.903)

0.019

Fig. 1

Kaplan–Meier survival analyses of FGFR1, FGFR4, and KLB in pancreatic cancer cohorts 1 and 2. Green represents expression ≥ the median, while blue represents expression < the median. Overall survival by expression of FGFR1 (a), KLB (b), and FGFR4 (c) in cohort 1. Overall survival by expression of FGFR1 (d) in cohort 2. FGFR fibroblast growth factor receptor, KLB klotho beta

Table 2

Multivariate analysis of FGFR-related genes for overall survival in cohort 1

Factors

Hazard ratio (95% CI)

P value

FGFR1

 FGFR1 (high vs. low)

0.524 (0.281–0.977)

0.042

 Tumor grade (1, 2 vs. 3, 4)

0.585 (0.337–1.016)

0.057

 Tumor stage (1, 2 vs. 3, 4)

0.814 (0.427–1.548)

0.530

FGFR4

 FGFR4 (high vs. low)

0.975 (0.516–1.842)

0.937

 Tumor grade (1, 2 vs. 3, 4)

0.514 (0.263–1.002)

0.051

 Tumor stage (1, 2 vs. 3, 4)

1.109 (0.614–2.001)

0.732

KLB

 KLB (high vs. low)

0.640 (0.375–1.093)

0.102

 Tumor grade (1, 2 vs. 3, 4)

0.547 (0.316–0.945)

0.031

 Tumor stage (1, 2 vs. 3, 4)

1.082 (0.606–1.931)

0.791

Expression and survival analysis of FGFR genes in discovery cohort 2

The potential significance of the FGFR-pathway genes was further evaluated in cohort 2. Similarly, logR expression values of the five FGFR-related genes were dichotomized according to their medians (Additional file 1: Figure S3). Consistent with the results in cohort 1, the highest median expression was observed for FGFR1. Of note, of all five genes, only patients with FGFR1 expression had significantly better overall survival by Kaplan–Meier analysis (Fig. 1d).

Expression and survival analysis of FGFR genes in discovery cohort 3

The TCGA pancreatic cancer dataset, which includes data from 179 pancreatic cancer patients, was selected as cohort 3. Overexpression of FGFR1, KLB, FGF19, FGFR4, and FGF21 was identified in 7 (4%), 7 (4%), 6 (3%), 5 (2.8%), and 2 (1.1%) patients, respectively (Additional file 1: Figure S4A). Notably, only FGFR1 overexpression was significantly associated with better overall (P = 0.0158) and disease-free survival (P = 0.006) (Additional file 1: Figure S4B).

FGFR1 immunolabeling in the validation cohort

Representative IHC images of FGFR1-positive and -negative cases from the validation cohort are depicted in Fig. 2a, b, respectively. Thirty (15.7%) cases were strongly FGFR1-positive, and 118 (61%) were moderately/weakly positive. Forty-three cases (22.5%) were negative for FGFR1 expression.
Fig. 2

Immunohistochemistry and Kaplan–Meier survival analysis of FGFR1 in the validation cohort of 205 pancreatic cancer patients. a, b Represent immunohistochemistry results of FGFR1-positive and -negative cases, respectively. c Overall survival of pancreatic cancer patients in the discovery cohort with high and low FGFR1 (c). FGFR: fibroblast growth factor receptor

Univariate and multivariate analysis for overall survival

According to the statistical analysis, no significant associations were observed between FGFR1 positivity and poor clinicopathological features, including bile duct invasion, duodenal invasion, perineural invasion, lymphovascular invasion, and lymph node metastasis. However, in univariate analysis, overall survival was significantly associated with age (HR 1.451, 95% CI 1.073–1.961, P = 0.016), bile duct invasion (HR 1.469, 95% CI 1.099–1.963, P = 0.009), lymphovascular invasion (HR 1.455, 95% CI 1.088–1.944, P = 0.011), lymph node metastasis (HR 2.495, 95% CI 1.811–3.436, P < 0.001), and FGFR1 expression (HR 0.590, 95% CI 0.415–0.839, P = 0.003) (Table 3). Furthermore, in the multivariate analysis, age (HR = 1.587, 95% CI 1.130–2.230, P = 0.008), bile duct invasion (HR 1.657, 95% CI 1.211–2.269, P = 0.002), lymph node metastasis (HR 2.360, 95% CI 1.665–3.344, P < 0.001), and FGFR1 expression (HR 0.677, 95% CI 0.471–0.972, P = 0.035) were predicted as significant prognostic biomarkers for overall survival in pancreatic cancer. Notably, FGFR1 expression was the only prognostic biomarker for better overall survival (i.e., HR < 1) (Table 3).
Table 3

Cox regression analysis for overall survival in 205 pancreatic cancer patients

 

P value

HR

Univariate Analysis

P value

HR

Multivariate analysis

95.0% CI for HR

95.0% CI for HR

Lower

Upper

Lower

upper

Age, years (≥ 60 vs. < 60)

0.016

1.451

1.073

1.961

0.008

1.587

1.130

2.230

Gender

0.235

1.191

0.892

1.591

    

Tumor size, cm (≥ 2 vs. < 2)

0.241

1.534

0.751

3.135

    

Differentiation (well/moderate vs. poor)

0.076

1.428

0.964

2.115

    

Extension (confined vs. peripancreatic soft tissue)

0.061

1.898

0.970

3.714

    

Bile duct invasion (absent vs. present)

0.009

1.469

1.099

1.963

0.002

1.657

1.211

2.269

Duodenum invasion (absent vs. present)

0.074

1.303

0.975

1.742

    

Lymphovascular invasion (absent vs. present)

0.011

1.455

1.088

1.944

0.098

1.320

.950

1.834

Perineural invasion (absent vs. present)

0.086

1.403

.953

2.064

    

Lymph node metastasis (absent vs. present)

< 0.001

2.495

1.811

3.436

< 0.0001

2.360

1.665

3.344

Tumor stagea

0.059

1.382

0.988

1.933

    

FGFR1 (positive vs. negative)

0.003

0.590

0.415

0.839

0.035

0.677

0.471

0.972

aTumor stage was not included for multivariate analysis because tumor size, in addition to bile duct and duodenal invasion and extension (confined vs peripancreatic soft tissue extension), are components of T stage

Discussion

The main finding of this study is that FGFR1 protein expression defines clinically distinct subtypes of pancreatic cancer. FGFR1-positive cases showed better overall survival than FGFR1-negative cases. To the best of our knowledge, this study is the first to demonstrate the clinical significance of FGFR1 overexpression in pancreatic cancer.

The clinical significance of FGFR1 overexpression has not been thoroughly investigated in pancreatic cancer for two reasons: (1) KRAS mutation, which does not have any targeted solution, is almost universal in pancreatic cancer; (2) FGFR1 overexpression is not exclusive with KRAS mutation [17, 20]. Although, recent genomic and transcriptomic studies identified new subtypes of PADC, but prognostic role of FGFR1 is not highlighted. For instance, Bailey and colleagues demonstrated that KrasG12D/+;Trp53fl/+ mutant subtype (containing group of genes with FGFR1 expression) showed less aggressive clinical outcome compared to KrasG12D/+;Trp53fl/+;TAp63fl/fl mutant subtype (containing group of genes without FGFR1 expression) in pancreatic cancer [21]. Furthermore, another transcriptomic profiling study classified PADC patients into L1–L6 subtypes. Interestingly, the L5 subtype which showed most favorable clinical outcome from the rest of the molecular subtypes was also enriched with FGFR1 pathway related genes [22].

Our finding can have immediate clinical ramifications. In pancreatic cancer, FGFR1 is the most frequently altered receptor of the four FGFR receptors, and, using readily applicable immunohistochemistry methods, FGFR1 can be used to classify pancreatic cancer into FGFR1-positive and -negative subtypes. As FGFR1-positive pancreatic cancer has better prognosis, FGFR1 can be used as an independent predictor of better overall survival in pancreatic cancer patients. Moreover, FGFR1-based subclassification of pancreatic cancer may lead to new therapeutic approaches for the FGFR1-positive subtype. For example, it may be possible to target FGFR1 using antibody in strongly FGFR1-positive pancreatic cancer, in the same manner in which HER2 is targeted using anti-HER2 antibodies in HER2-positive breast cancer.

Only a few previous studies have examined FGFR1 expression in pancreas cancers, and they reported a wide range of FGFR1 positivity (4–57%) [18, 19, 23]. Lehnen and colleagues observed that 4% (5/125) of pancreatic cancer patients showed FGFR1 expression, and amplification was noted in 2.6% of the cases (4/155) [18]. In contrast, Kornmann et al. reported that 57% (4/7) of pancreas cancers showed immunoreactivity for FGFR1 IIIc [19]. Our study is unique in that we evaluated FGFR1 expression based on the intensity of FGFR1 labeling, and we observed strong FGFR1 positivity in 15.7% (30 cases) and moderate/weak FGFR1 positivity in 61.8% (118 cases) in a cohort of Korean pancreatic cancer patients. Using only the strong FGFR1 expression group, the frequency of FGFR1 labeling was higher than the results of Lehnen and colleagues’ study. However, if we include moderate/weak FGFR1 labeling, the frequency was similar to that of Kornmann’s study. This wide range of FGFR1 labeling results may be plausibly explained by different FGFR1 expression rates based on different ethnic groups (Korean and Western populations), use of different antibody clones, or different cutoffs for FGFR1 labeling.

Conclusion

In summary, FGFR1 overexpression, evaluated by IHC, may be used as a prognostic biomarker for overall survival in pancreatic cancer patients. Moreover, FGFR1 overexpression may define a subset of pancreatic cancer, leading to new therapeutic approaches.

Notes

Authors’ contributions

FH, YNS, MAK and FY carried out experiments and analyzed the data. YNS and IP carried out statistical analyses. SMA and SMH contributed to the conception and design of the study. FH, SMA and SMH contributed to the writing of the manuscript. All authors read and approved the final manuscript.

Acknowledgements

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

The links of data are mentioned in “Methodology” section.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Not applicable.

Funding

This research was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute, funded by the Ministry of Health and Welfare (HI16C1985) and by a grant from Gachon University Gil Medical Center (FRD2016-20).

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary material

12967_2018_1743_MOESM1_ESM.docx (220 kb)
Additional file 1. Additional figures and table.

References

  1. 1.
    Touat M, Ileana E, Postel-Vinay S, André F, Soria J-C. Targeting FGFR signaling in cancer. Clin Cancer Res. 2015;21:2684–94.CrossRefGoogle Scholar
  2. 2.
    Ho HK, Németh G, Ng YR, Pang E, Szántai-Kis C, Zsákai L, et al. Developing FGFR4 inhibitors as potential anti-cancer agents via in silico design, supported by in vitro and cell-based testing. Curr Med Chem. 2013;20:1203–17.CrossRefGoogle Scholar
  3. 3.
    Leung HY, Gullick WJ, Lemoine NR. Expression and functional activity of fibroblast growth factors and their receptors in human pancreatic cancer. Int J Cancer. 1994;59:667–75.CrossRefGoogle Scholar
  4. 4.
    Yoo C, Kang J, Kim D, Kim K-P, Ryoo B-Y, Hong S-M, et al. Multiplexed gene expression profiling identifies the FGFR4 pathway as a novel biomarker in intrahepatic cholangiocarcinoma. Oncotarget. 2017;8:38592–601.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Ahn S-M, Jang SJ, Shim JH, Kim D, Hong S-M, Sung CO, et al. Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification. Hepatology. 2014;60:1972–82.CrossRefGoogle Scholar
  6. 6.
    Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res. 2010;70:2085–94.CrossRefGoogle Scholar
  7. 7.
    Miura S, Mitsuhashi N, Shimizu H, Kimura F, Yoshidome H, Otsuka M, et al. Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma. BMC Cancer. 2012;12:56.CrossRefGoogle Scholar
  8. 8.
    Fumarola C, Cretella D, Monica SL, Bonelli MA, Alfieri R, Caffarra C, et al. Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. Oncotarget. 2017;8:91841–59.CrossRefGoogle Scholar
  9. 9.
    Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010;10:116–29.CrossRefGoogle Scholar
  10. 10.
    Helsten T, Elkin S, Arthur E, Tomson BN, Carter J, Kurzrock R. The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing. Clin Cancer Res Off J Am Assoc Cancer Res. 2016;22:259–67.CrossRefGoogle Scholar
  11. 11.
    Babina IS, Turner NC. Advances and challenges in targeting FGFR signalling in cancer. Nat Rev Cancer. 2017;17:318–32.CrossRefGoogle Scholar
  12. 12.
    Porta C, Giglione P, Liguigli W, Paglino C. Dovitinib (CHIR258, TKI258): structure, development and preclinical and clinical activity. Future Oncol Lond Engl. 2015;11:39–50.CrossRefGoogle Scholar
  13. 13.
    Chae YK, Ranganath K, Hammerman PS, Vaklavas C, Mohindra N, Kalyan A, et al. Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application. Oncotarget. 2016;8:16052–74.PubMedCentralGoogle Scholar
  14. 14.
    Gozgit JM, Wong MJ, Moran L, Wardwell S, Mohemmad QK, Narasimhan NI, et al. Ponatinib (AP24534), a multitargeted Pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Mol Cancer Ther. 2012;11:690–9.CrossRefGoogle Scholar
  15. 15.
    Dhillon S. Nintedanib: a review of its use as second-line treatment in adults with advanced non-small cell lung cancer of adenocarcinoma histology. Target Oncol. 2015;10:303–10.CrossRefGoogle Scholar
  16. 16.
    Hamberg P, Verweij J, Sleijfer S. (Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor. Oncologist. 2010;15:539–47.CrossRefGoogle Scholar
  17. 17.
    Cancer Genome Atlas Research Network. Electronic address: andrew_aguirre@dfci.harvard.edu, Cancer Genome Atlas Research Network. Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell. 2017;32:185–203.e13.Google Scholar
  18. 18.
    Lehnen NC, von Mässenhausen A, Kalthoff H, Zhou H, Glowka T, Schütte U, et al. Fibroblast growth factor receptor 1 gene amplification in pancreatic ductal adenocarcinoma. Histopathology. 2013;63:157–66.CrossRefGoogle Scholar
  19. 19.
    Kornmann M, Ishiwata T, Matsuda K, Lopez ME, Fukahi K, Asano G, et al. IIIc isoform of fibroblast growth factor receptor 1 is overexpressed in human pancreatic cancer and enhances tumorigenicity of hamster ductal cells. Gastroenterology. 2002;123:301–13.CrossRefGoogle Scholar
  20. 20.
    Zeitouni D, Pylayeva-Gupta Y, Der CJ, Bryant KL. KRAS mutant pancreatic cancer: no lone path to an effective treatment. Cancers (Basel). 2016;8:E45.CrossRefGoogle Scholar
  21. 21.
    Bailey P, Chang DK, Nones K, Johns AL, Patch A-M, Gingras M-C, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531:47–52.CrossRefGoogle Scholar
  22. 22.
    Zhao L, Zhao H, Yan H. Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes. BMC Cancer. 2018;18:603.CrossRefGoogle Scholar
  23. 23.
    Kobrin MS, Yamanaka Y, Friess H, Lopez ME, Korc M. Aberrant expression of type I fibroblast growth factor receptor in human pancreatic adenocarcinomas. Cancer Res. 1993;53:4741–4.PubMedGoogle Scholar

Copyright information

© The Author(s) 2018

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  1. 1.Department of BiosciencesCOMSATS UniversityIslamabadPakistan
  2. 2.Department of PathologyAsan Medical Center, University of Ulsan College of MedicineSeoulRepublic of Korea
  3. 3.Division of Oncology, Department of Internal MedicineGachon University Gil Hospital, Gachon University Gil Medical CenterIncheonRepublic of Korea
  4. 4.Department of Genome Medicine and Science, College of Medicine, Gachon Institute of Genome Medicine and ScienceGachon UniversitySeongnamRepublic of Korea

Personalised recommendations